Firefly Neuroscience (AIFF) highlights two impactful studies that demonstrate the utility of advanced Resting Electroencephalograms and ...

Growing body of clinical evidence supports use of Company’s FDA-Cleared BNA™ platform to provide objective measures of drug efficacy and cognitive change, driving innovation in brain health Company ...

Firefly Neuroscience, Inc. (NASDAQ:AIFF – Get Free Report) traded down 3.9% during mid-day trading on Tuesday . The stock traded as low as $3.43 and last traded at $3.70. 523,068 shares changed hands ...

EconoTimes is a global, independent publication that delivers comprehensive news, analysis, and insights on the economy, finance, and markets. Based in Korea, we offer a unique perspective on global ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

Highlights,Firefly’s BNA™ platform successfully estimates biological brain age using cognitive ERP data.,New method could revolutionize early screening for Alzheimer's and dementia risk.,Research ...

On Tuesday, Firefly Neuroscience Inc (AIFF) stock saw a modest uptick, ending the day at $3.15 which represents a slight increase of $1.25 or 65.79% from the prior close of $1.9. The stock opened at ...

KENMORE, N.Y., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly" or the "Company") (NASDAQ: AIFF), an Artificial Intelligence ("AI") company ...

Measuring brain age with EEG and BNA™ could lead to a proactive and scalable approach to early screening for Alzheimer's patients KENMORE, N.Y., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, ...

KENMORE, N.Y., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI ...

Firefly Neuroscience shares doubled to $3.90 Tuesday after the company said it is advancing its research used to assess a patient's brain age--an estimation of the biological age of a person's ...